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Abstract
Osteoporosis is a complex metabolic disease with a strong 
genetic component which results in a decrease in bone mineral 
density and deterioration in the microarchitecture of bone, 
leading to an increased risk of fractures. During the last decade, 
a number of genetic studies of the Maltese population were 
performed to determine a potential genetic component which 
increases the individual’s susceptibility to osteoporosis. Both 
family and population case-control approaches were used. 
Linkage analysis using large affected families has identified a 
region on chromosome 11p12, following which functional studies 
have shown that variations within two genes found in that region 
namely, TRAF6 and CD44, affect gene expression, and, more 
specifically, pre-mRNA splicing in the case of CD44.   This is the 
first report of strong suggestive linkage of 11p12 to osteoporosis. 
Using the candidate gene approach, selected candidate genes, 
which had been studied in other populations and been found to 
increase susceptibility to osteoporosis to varying degrees in some 
of them, included those coding for the vitamin D and oestrogen 
receptors (VDR & ER1), osteoprotegerin (TNFRSF11B), 
collagen type 1 (COL1A1), methylenetetrahydrofolate reductase 
(MTHFR) and lipoprotein receptor related protein (LRP)-5. 
In the Maltese population, the most significant result showed 
that a polymorphism in the promoter region of TNFRSF11B, 
which codes for osteoprotegerin, had a significant effect on 
bone mineral density, thus increasing the susceptibility to 
osteoporosis. These studies have shown that variations within 
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three different genes, namely TRAF6, CD44 and TNFRSF11B, 
all involved in osteoclast biology, might increase the risk of 
osteoporosis and could therefore serve as targets for novel 
therapeutic agents.  
Introduction
The identification of genes that are responsible for common 
human diseases such as diabetes, osteoporosis, heart disease, 
epilepsy, obesity and coeliac disease, among others, poses 
the greatest challenge to geneticists. The aetiology of these 
diseases is known to be complex and includes both genetic 
and environmental factors. Each of these factors alone has a 
modest effect, but then cumulative effects, especially when a 
certain threshold is exceeded, result in disease. Susceptibility 
to disease is increased by the interactions of variants within 
the same and/or different genes which are modified by various 
environmental factors, including diet and lifestyle habits. Other 
confounding factors, such as heterogeneity, phenocopies, genetic 
imprinting and penetrance, influence the effect of the genotype 
on the phenotype and further complicate the identification of 
susceptibility genes. These factors make it more difficult to reach 
conclusions and to replicate results using current approaches. 
Three common approaches used for the identification of 
susceptibility genes are the case-control (studying candidate 
genes), the genomic linkage (also known as gene-mapping or 
family studies) and the genome-wide association study (GWAS) 
approach. For a case-control study, candidate genes are most 
often selected by knowledge of physiology or by prior evidence 
from association studies performed in other populations, thus 
assuming a priori that these could increase the risk of disease. 
Single nucleotide polymorphisms (SNPs), found within the 
selected genes, are studied in a random sample of affected 
individuals while a group of sex- and age-matched unaffected 
individuals is used as controls. Significant association is 
found if allele frequencies differ significantly between affected 
individuals and normal controls, where an over-representation 
in the former group indicates a risk allele for the disease. 
The second approach that has been used in the study of the 
Maltese population is the linkage approach or a family study. 
In genome-wide linkage analysis, no knowledge of candidate 
genes is required and the objective is to identify a novel gene 
responsible for the disease (and/or a disease-causing genetic 
variation) when located at a chromosomal region which is 
inherited with the phenotype. A number of polymorphic markers 
spaced across the genome are analysed within one or a group of 
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families, with one or more affected individuals. If a marker on 
a chromosome happens to be very close to the disease-causing 
mutation, it will be observed to segregate with the phenotype in 
a family, therefore said to be in linkage. The closer the marker 
is to the disease-causing mutation, the less likely it is to be 
separated by meiotic recombination from one generation to 
the next. Using a single, but large extended family, has proved 
useful to identify rare but high risk alleles within novel genes, 
sometimes not previously considered as candidate genes.1 
A more recent approach known as genome-wide association 
study (GWAS) is currently being used worldwide.2 Here a large 
number of SNPs (usually around 500,000) spread across the 
whole genome are tested for association within a group of 
affected individuals and normal controls. The results show 
chromosomal regions which should be further investigated 
for the presence of any causative genes and variations within 
them.  
Genome-wide high density SNPs can also be used in families 
and in single extended families, and are useful tools for what 
is known as homozygosity mapping. Homozygosity linkage is 
very powerful to detect rare recessive disease genes, especially 
in consanguineous families, but it has also been found useful 
for complex disorders. 
The heritability of osteoporosis involves the interactions 
of different genes modified by environmental factors, such 
as calcium and vitamin D intake, physical activity, smoking 
and medications. Over the past fifteen years, a large number 
of genetic studies have been performed worldwide using both 
association and linkage approaches, but until now, no major 
susceptibility genes were identified and confirmed. Candidate 
genes studied are those primarily involved in various biological 
processes in bone biology such as those coding for various 
receptors (VDR, ER1, LRP5), cytokines (IL6), growth factors 
(TGF-β, IGF-1), and structural proteins (COL1A1)3-9. Other 
studied genes include those causing other forms of bone diseases 
such as the SOST gene which causes sclerosteosis.10
Genetic association studies 
One of the most extensively studied genes is that coding 
for the vitamin D receptor (VDR), which is a nuclear receptor 
responsible for the initiation of transcription of target genes 
upon stimulation by the active form of vitamin D. The most 
common single nucleotide polymorphisms (SNPs) studied for an 
association with low bone mineral density include a start codon 
polymorphism found in exon 2 (Fok I), three SNPs identified 
by endonucleases BsmI, ApaI and TaqI at the 3` end of the 
gene and a functional binding site for the intestinal-specific 
transcriptional factor Cdx-2 in the 1a promoter region.11-14
Conflicting results were obtained from studies performed 
in different populations, where this lack of concordance can be 
attributed to a lack of sample power, population stratification, 
heterogeneity between different populations, effects of other 
confounding factors and technical problems, such as lack of 
harmonisation of methodologies used in different studies. 
Calcium intake was observed to have an effect on the influence 
of various polymorphisms on BMD, including that of the B 
allele for the BsmI polymorphism of the VDR gene, which was 
correlated with a low BMD only in the presence of low calcium 
intake in the Dutch population.15 The same observation was 
made for the G allele (with low BMD) of the Cdx-2 polymorphism 
in the promoter region. No statistically significant association 
was observed between mean BMD and any of the studied SNPs 
within the VDR gene in the Maltese population16,17, but trends 
were similar to those reported in other studies.3,15 A significant 
odds ratio of 2.7 (95% CI: 1.7 -4.5; p<0.001) was observed for the 
G allele (BsmI polymorphism), indicating that this allele could 
increase the risk of low BMD17 in the Maltese population.  
 Other candidate genes studied in the Maltese population 
were those encoding for the oestrogen receptor (ER)-1, collagen 
type 1a1, methylenetetrahydrofolate reductase (MTHFR)18 
and lipoprotein receptor-related protein (LRP)-5. None of 
the polymorphisms studied in these genes were significantly 
associated with an increased risk of osteoporosis.
Significant differences were observed in the Maltese 
population in the distribution of genotype frequencies between 
women with low BMD and normal controls for the T950C 
polymorphism found in the promoter region of the TNFRSF11B 
gene, which codes for the decoy receptor osteoprotegerin (OPG). 
OPG is a secreted glycoprotein of the tumour necrosis factor 
(TNF) superfamily that controls osteoclastogenesis by binding to 
RANKL thus preventing its interaction with RANK on osteoclast 
progenitors and promoting apoptosis (Figure 1).19
Genotype frequencies for the T950C polymorphism were 
similar to those observed in the Danish, Slovenian and Swedish 
populations.20-22 In the Maltese population, the frequency of the 
TT genotype was significantly over-represented in individuals 
having a  low BMD (83%) while the CC genotype was found in 
59% of the normal controls.23 Also for another polymorphism 
in the first exon of the gene (G1181C), the GG genotype was 
found more frequently in the group of osteopenic/osteoporotic 
women, although this was not statistically significant. Similar 
observations were reported in the Danish population where the G 
allele was found to be significantly more common in osteoporotic 
patients.20 Significant odds ratios were also observed for the 
T950C and G1181C polymorphisms, when comparing genotypes 
in affected and normal postmenopausal women. The A-T-G 
haplotype was also significantly associated with an increased risk 
of a low BMD while the A-C-C haplotype was shown to have a 
protective role. It is not known yet whether this polymorphism 
in the promoter region of the TNFRSF11B gene is functional 
or whether it is in linkage disequilibrium with another as yet 
unknown functional variant found elsewhere within this gene. 
Linkage studies 
The other approach used in our genetic studies, which 
yielded valuable and new data, was the linkage approach. A 
family based linkage analysis was performed using 27 members 
from two Maltese families (15 females and 12 males) with 
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multiple affected individuals.  The initial genome-wide scan 
was performed using a set of 400 polymorphic markers spread 
across the 22 autosomes and X-chromosome. The osteoporosis 
phenotype was defined according to WHO criteria using a 
t-score of < -2.5 as threshold for post-menopausal women and 
older men (>50 years) while z-scores were used for the younger 
generations as suggested by the International Society of Clinical 
Densitometry.24 Following the initial analysis, fine-mapping 
was performed at the indicated chromosomal regions only, by 
increasing the number of tested markers to be able to identify 
any suspected genes.  
Strong suggestive linkage was observed to chromosome 
11p12 where haplotypes, inherited in an autosomal dominant 
fashion with a number of recombination events occurring 
close to this region25 were observed in each family.  This was 
the first time that strong suggestive linkage was reported to 
11p12 (OMIM: 611739; BMD8; http://www.ncbi.nlm.nih.gov/
entrez/dispomim.cgi?id=611739). Subsequently other studies, 
which included a meta-analysis of nine genome-wide scans26 
and a recent genome-wide analysis using over 300,000 SNPs, 
where a non-significant association to fractures was observed 
with a SNP within the LRP-4 gene27, only showed weak evidence 
of linkage to this region.   The same region on chromosome 
11p12 was also linked to a number of inflammatory disorders 
including rheumatoid arthritis, coeliac and inflammatory bowel 
disease.28-31  The same locus was also linked with coeliac disease 
in a Maltese family where linked variants were identified by 
sequencing genes at this locus.30 The above mentioned diseases 
were excluded from the two osteoporotic Maltese families used 
in this study. Such observations could support the hypothesis 
that a common inflammatory process controlled by genes in this 
region might be responsible for the onset of these diseases. 
Twenty-two genes were found at this locus, with the best 
candidates being those coding for the TNF receptor associated 
factor (TRAF)-6 (MIM 602355) and CD44 (MIM 107269), 
with TRAF6 being closer to the indicated marker. TRAF6 plays 
a very important role in the differentiation and activation 
of osteoclasts by interacting with the cytoplasmic domain of 
RANK and activating transcription mediated through at least 
three signal transduction cascades (Figure 1).32 TRAF6 might 
also be a key molecule involved in the activation of osteoclasts 
following stimulation by a number of inflammatory cytokines, 
thus further supporting the hypothesis that osteoporosis results 
from a mild inflammatory process. RANK/RANKL and TRAF6 
were reported to play a very important role in what is known as 
osteoimmunology, where both bone physiology and immunology 
interact and share various molecules.33 
The TRAF6 gene was sequenced and three polymorphisms 
were identified, two of which were found in introns, and an 
A to T variation found at position -721 upstream from the 
transcriptional start site.17, 25 
This polymorphism was further tested for its possible 
functional effects on gene expression because it was found in 
3 (33%) of affected family members from one family, but only 
in 1% of the general population. Reporter gene assays showed 
that gene expression was significantly increased in the presence 
of the T allele when compared to wild-type A allele17, thus 
suggesting increased osteoclastogenesis and therefore increased 
bone resorption. Further experiments were performed to test 
whether other transcriptional factors that bind further upstream 
in the promoter region might affect expression in the absence or 
presence of this variation. GATA-1 was observed to be a potential 
enhancer of gene expression in wild-type alleles but not in the 
presence of the T allele.34 
 Another candidate at 11p12 is the CD44 gene, which consists 
of a total of 18 exons and shows extensive heterogeneity when it 
is expressed due to alternative splicing. This molecule was found 
to have an important role in the fusion of macrophages to form 
multinucleated cells, such as osteoclasts, and was also found to 
activate signal transduction.35 The CD44 gene was sequenced 
and six known SNPs were found in both introns and exons, but 
none of these was linked to the inherited haplotype. The most 
significant finding was an already known G/A synonymous 
SNP (rs11033026) found 32 nucleotides upstream from the 
exon-intron junction in exon 9. This SNP was found linked to 
the STR allele in all affected family members (from one family), 
with the exception of one member. In the general Maltese 
population at birth, a frequency of 2.38% with a minor allele 
frequency of 0.012 was determined. This polymorphism was 
reportedly absent in European Caucasians but was found in 
Sub-Saharan Africans, African-Americans and Asians (minor 
allele frequencies 0.336, 0.115, 0.012, respectively) (http://www.
ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11033026).
Since this polymorphism does not result in an amino acid 
change, it was hypothesised that it could affect pre-messenger 
RNA (pre-mRNA) splicing during transcription. Similar 
variations affecting splicing were reported to cause other 
diseases, such as cystic fibrosis and neurofibromatosis type 1.36,37 
In vitro experiments performed to test this hypothesis showed 
that the variant affected RNA splicing in mouse macrophages, 
thus possibly increasing risk of osteoporosis in this family.38 
Figure 1: Osteoclast activation through 
RANK/RANKL system17
Malta Medical Journal    Volume 21   Issue 04   December 2009 9
Macrophages are the pre-cursors of osteoclasts, and therefore 
a shift in the balance between different CD44 isoforms might 
affect their function and mechanisms, possibly cell fusion and 
migration. DNA variations found in non-coding regions of 
genes should not be underestimated. More supporting evidence 
is emerging to indicate that these variants can still affect the 
phenotype by affecting either RNA splicing or protein folding 
without changing the amino acid sequence.39 
General conclusions 
A number of polymorphisms were identified in three 
different genes, the TNFRSF11B, TRAF6 and CD44, all 
involved in osteoclast biology. Two of these polymorphisms 
found within the TRAF6 and CD44 genes were also tested 
functionally and were found to affect gene expression and pre-
mRNA splicing, thus possibly increasing the risk of disease in 
affected individuals. In different ways, the protein products of 
these genes are all involved in osteoclast differentiation and 
activation. TRAF6 is a key player in the activation of various 
signal transduction cascades leading to increased osteoclast 
activation following stimulation through RANK. Increased 
expression of TRAF6 (or decreased degradation) results in 
increased osteoclastogenesis due to activation of different 
cascades. Conversely OPG (TNFRSF11B) is a negative regulator 
of osteoclastogenesis and thus decreased quantities or decreased 
binding to RANKL will lead to increased osteoclast activity. 
In a different way, CD44 isoforms can also affect osteoclast 
activity possibly by affecting fusion during their formation or 
even their migration. These findings show the importance of the 
RANK/RANKL/OPG system involved in osteoclast differentiation 
and activation. Both TRAF6 and OPG are targets for treatments 
aimed at controlling bone resorption, decreasing inflammatory 
bone loss and osteoporosis. Exogenous OPG has been used 
successfully in postmenopausal women as an antiresorptive 
agent showing its potential therapeutic use.19  TRAF6 inhibitors 
have already been suggested as having a potential therapeutic 
use to control inflammation not only in osteoporosis but also in 
other diseases such as periodontitis, osteolytic conditions, cystic 
fibrosis, viral infections and connective tissue destruction.40 
Lately, biphenylcarboxylic acid was reported to inhibit TRAF 
recruitment to pro-inflammatory cytokine receptors and was 
found to prevent translocation of TRAF6 to the cell membrane.41 
The role of CD44 in osteoporosis needs to be further studied. 
It can, however, be a potential therapeutic target with different 
isoforms being used for diagnostics purposes, possibly also with 
a prognostic value for bone tumours.42 
Genetic studies together with functional studies of potential 
candidates will help to identify new metabolic pathways that 
might be involved in the pathogenesis of disease, thus assisting 
in the development of new and more effective treatments. 
Extending these genetic studies to patients, who have suffered 
fractures, irrespective of their BMD status, might help elucidate 
further the genetic basis of bone disease in the Maltese 
population. 
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